Pharmaceuticals
Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research
SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announcedClinical Cancer Research, a journal of the American Association for Cancer Research (AACR), published the data from a phase I clinical study of the company's proprietary HER2 bispecific antibody KN026 fo...
2022-02-24 09:41
3413
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
SAN FRANCISCO and SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-02-24 08:00
4525
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and ...
2022-02-23 23:00
2974
Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II ("LAD-II"). Orpha Labs AG is w...
2022-02-23 21:27
3340
SyMap Medical Ltd Completed Enrollment in SMART Study for the Treatment of Uncontrolled Hypertension
SUZHOU, China, Feb. 23, 2022 /PRNewswire/ -- SyMap Medical Ltd. (Suzhou, China) announced successful completion of enrollment in the company's SMART Study (S ympatheticMapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811), using the SyMapCath I™ Catheter/SYMPIONEER S1™ Ma...
2022-02-23 21:00
2820
Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced interim data from a Phase II clinical trial of STP705, a siRNA (small interfering RNA) therapeutic, ...
2022-02-23 17:53
3640
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group"; stock code: 2096.HK), announces a positive profit alert. Based on a preliminary assessment of the Group's unaudited consolidated management accounts for the ...
2022-02-23 16:22
3970
Radiaction Opens First EU Radiation Protection Center of Excellence in Collaboration with Mazowiecki Hospital in Ostrołęka, Poland
TEL AVIV, Israel, Feb. 22, 2022 /PRNewswire/ -- Radiaction Medical Ltd
2022-02-23 10:00
2989
RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced that it has signed a Material Transfer Agreement (MTA) with one of the largest global pharmaceutical companies Eli Lilly and Company (hereinafter referred to as "Eli Lilly...
2022-02-22 20:52
4422
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP
BEIJING, Feb. 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the first patient has been dosed in Phase II clinical trial of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of primary immune thrombocyto...
2022-02-22 17:09
2705
111 to Announce Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on March 17, 2022 - Conference Call to Follow
SHANGHAI, Feb. 22, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2022-02-22 16:38
2405
Nippon Express Obtains GDP Certification for Temperature-controlled Facility at Kansai International Airport
TOKYO, Feb. 22, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereinafter "Nippon Express"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification, effectiveJanuary 11, for NX-PHARMA Logistics Hub Kansai Airport, a temperature-controlled fa...
2022-02-22 15:00
3388
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment ofAlmira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengt...
2022-02-21 22:00
2633
Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development
* Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the outcome of its relentless focus on R&D * Attributed to export upswing of Nabota, KRW 1.1 trillion overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs SEOUL, So...
2022-02-21 22:00
2806
Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced the publication of preclinical research of AN3025 (anti-hTNFR2）...
2022-02-21 21:00
2609
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
SAN FRANCISCO and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2022-02-21 08:00
4044
Keymed Bio Joins Hang Seng Family of Indexes
HONG KONG, Feb. 18, 2022 /PRNewswire/ -- According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...
2022-02-18 22:10
7081
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China
NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor,...
2022-02-18 22:00
4442
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...
2022-02-18 08:19
2223
Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia
TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...
2022-02-17 21:00
2025
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
16130
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
7619
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
7192
